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The origins of genome instability in
cancer remain poorly understood. Fagan-
Solis et al. reveal a p53-independent
genome integrity checkpoint pathway
mediated by Mre11 that protects against
genome instability in breast cancer.
Mre11 dysfunction in breast cancer
models induces a genomic loss signature
and vulnerability to PARP and ATR
inhibitors.
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The Mre11-Rad50-Nbs1 complex is a DNA double-
strand break sensor that mediates a tumor-suppres-
sive DNA damage response (DDR) in cells undergo-
ing oncogenic stress, yet themechanisms underlying
this effect are poorly understood. Using a genetically
inducible primary mammary epithelial cell model, we
demonstrate that Mre11 suppresses proliferation
and DNA damage induced by diverse oncogenic
drivers through a p53-independent mechanism.
Breast tumorigenesis models engineered to express
a hypomorphic Mre11 allele exhibit increased levels
of oncogene-induced DNA damage, R-loop accumu-
lation, and chromosomal instability with a character-
istic copy number loss phenotype. Mre11 complex
dysfunction is identified in a subset of human triple-
negative breast cancers and is associated with
increased sensitivity to DNA-damaging therapy and
inhibitors of ataxia telangiectasia and Rad3 related
(ATR) and poly (ADP-ribose) polymerase (PARP).
Thus, deficiencies in the Mre11-dependent DDR
drive proliferation and genome instability patterns
in p53-deficient breast cancers and represent an op-
portunity for therapeutic exploitation.INTRODUCTION
Structural chromosomal instability (CIN) is a frequent hallmark of
clinically aggressive cancers, such as triple-negative (estrogen
receptor, progesterone receptor, and HER2-negative) breast
cancer (TNBC) and high-grade serous ovarian cancer (HGSOC),Cell R
This is an open access article under the CC BY-Nyet its etiology remains poorly understood (Cancer Genome
Atlas, N. and Cancer Genome Atlas Network, 2012; Jiang
et al., 2010; Jonkers et al., 2001). Cancers with high levels of
structural CIN are characterized by nearly universal disruption
of the p53 pathway and frequent genetic aberrations that
drive a hyper-proliferation phenotype (e.g., amplification of
c-Myc or Cyclin E and/or Rb1 deletion). Cancers with high
levels of CIN also have frequent perturbation of DNA damage
response (DDR) pathway genes (Knijnenburg et al., 2018),
although their relevance to genome instability and therapeutic
sensitivity in p53-deficient cancers remains unclear.
Oncogene-induced hyper-proliferation stimulates DNA repli-
cation stress (Bartkova et al., 2005, 2006; Di Micco et al.,
2006; Halazonetis et al., 2008), resulting in accumulation of
single- and double-strand breaks (DSBs) during S phase
(Gaillard et al., 2015; Hills and Diffley, 2014; Macheret and
Halazonetis, 2015) and activation of the DDR. The etiology of
oncogene-induced replication stress has been extensively
studied. Proposed mechanisms include nucleotide depletion,
oxidative stress, misregulated replication origin firing, re-replica-
tion, perturbed replication fork kinetics, and under-replicated
genomic DNA (Gaillard et al., 2015; Hills and Diffley, 2014; Kot-
santis et al., 2018). Recent evidence suggests that oncogene
expression stimulates genome-wide activation of ectopic
intragenic origins, which results in replication stress due to a
higher rate of transcription replication conflicts (TRCs)
(Macheret and Halazonetis, 2018). Furthermore, depletion of
RNA-DNA hybrids (i.e., R-loops) by RNase H overexpression
reduces the burden of oncogene-induced DSBs (Kotsantis
et al., 2016). Despite these advances, the relevance of path-
ways that regulate R-loop-mediated genome instability in
tumorigenesis models remains poorly understood.
The Mre11-Rad50-Nbs1 complex is a DSB sensor that lies
at the nexus between DNA repair and DDRs. TheMre11 complex
is critical for ataxia telangiectasia mutated (ATM) activation ateports 30, 1385–1399, February 4, 2020 ª 2020 The Authors. 1385
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
DSBs and downstream activation of G2/M and p53-dependent
G1/S cell cycle checkpoints (Oh and Symington, 2018; Stracker
and Petrini, 2011; Syed and Tainer, 2018). The nuclease and
structural functions of the Mre11 complex promote the resection
of DSBs to generate 30 overhangs, which are a prerequisite for
homologous recombination (HR)-mediated repair and replica-
tion fork stability (Hashimoto et al., 2011; Lemaçon et al., 2017;
Trenz et al., 2006). Although complete deficiency is lethal, hypo-
morphic alleles of Mre11 complex genes are causative for
ataxia-telangiectasia-like disorder and Nijmegan breakage syn-
drome and have helped to establish critical roles for this pathway
in suppression of replication-associated DSBs and response to
exogenous clastogens. Recent findings also implicate the
Mre11 complex and its closely associated nuclease, Sae2/
CtIP, in the resolution of R-loops in mammals (Chang et al.,
2018; Makharashvili et al., 2018).
Accumulating evidence supports a tumor-suppressive func-
tion for the Mre11 complex. Individuals with rare germline vari-
ants in Mre11 complex genes are at elevated risk of developing
breast cancer (Damiola et al., 2014; Heikkinen et al., 2006).
Although somatic mutations in Mre11 complex genes are infre-
quent in cancer (3%; Zehir et al., 2017), aberrantly reduced
protein expression has been identified in subsets of bladder,
colorectal, breast, and ovarian cancers (Bartkova et al., 2008;
Brandt et al., 2017; Choudhury et al., 2010; Situ et al., 2019;
Zaki et al., 2014). Mice expressing the hypomorphic Mre11ATLD1
allele also exhibit accelerated tumorigenesis driven by p53
mutation (Theunissen et al., 2003), Chek2 deficiency (Stracker
et al., 2008), and mammary-specific Her2 expression (Gupta
et al., 2013). Her2-driven breast cancers engineered to express
a hypomorphic Mre11 complex exhibit increased genome
instability and greater metastatic potential (Gupta et al., 2013).
The mechanisms for these diverse tumor-suppressive effects
have not been elucidated and may entail ATM- and p53-inde-
pendent pathways. Indeed, ATM-independent tumor suppres-
sion was recently demonstrated using mice with knockin of a
hypomorphic Nbs1 allele (Nbs1DB) (Balestrini et al., 2016).
Here, Mre11 complex dysfunction was associated with common
fragile site instability and dramatically increased genomic insta-
bility in the induced lymphomas. Collectively, these observations
highlight an important role for the Mre11 complex in tumor
suppression and protection against genome instability. A greater
understanding of these Mre11-dependent effects may have
important implications for classification of human tumors and
identification of potential therapeutic vulnerabilities.
The goal of this study was to characterize the effects of Mre11
complex dysfunction on oncogenic proliferation, DNA damage,
and genome instability in p53-proficient and p53-deficient
inducible breast cancer models. We use single-cell, whole-
genome sequencing to characterize the effect of Mre11
dysfunction on the landscape of Her2-induced genomic insta-
bility in mammary epithelial hyperplasia. We further establish
p53-independent effects of Mre11 in suppressing oncogene-
induced cell proliferation, DNA damage, and R-loops induced
by diverse oncogenic drivers. We characterize a murine model
of Rb1/Trp53/ breast cancers with Mre11 hypomorphism
that reveals abundant expression of R-loops and a marked
increase in genomic deletions relative to other types of chromo-1386 Cell Reports 30, 1385–1399, February 4, 2020somal rearrangements. Finally, drug sensitivity analyses of engi-
neered p53-deficient breast tumors with or without Mre11
dysfunction identify therapeutic vulnerabilities that may be clini-
cally exploitable.
RESULTS
Early Induction of Chromosomal Instability by
Oncogenic Stress in Primary Mammary Epithelial Cells
We previously demonstrated that breast cancers initiated by
Her2/Neu expression (abbreviated here as ‘‘Her2’’) develop
with shorter latency and increased levels of CIN in mice express-
ing a hypomorphic allele of Mre11 (Mre11ATLD1/ATLD1; abbrevi-
ated Mre11ATLD; Gupta et al., 2013). To investigate whether
Mre11 hypomorphism alters CIN patterns during early stages
of oncogenic hyperplasia, we established a system for propa-
gating primary murine mammary epithelial cells (pMMECs) on
lethally irradiated LA7 mammary stem cell feeder cells (Ehmann
et al., 1984; Jechlinger et al., 2009). Consistent with our previ-
ously reported in vivo findings, we observed significantly greater
Her2-induced proliferation in Mre11ATLD pMMECs relative to
wild-type (WT) pMMECs (Figure 1A). Because oncogene-
induced CIN during preneoplasia is stochastic and precedes
clonal expansion, analysis of CIN patterns requires a single
cell-based approach. Accordingly, we performed low-depth
(0.23), single-cell, whole-genome sequencing (scWGS) in
WT andMre11ATLD pMMECs 14 days after lentiviral transduction
with EGFP alone or EGFP+Her2 (Figure 1A). Copy number alter-
ations (CNAs) were detected at single-cell resolution by pooling
mapped reads into genomic bins with average size of 25 kb, us-
ing a previously described analysis pipeline (Garvin et al., 2015;
Martelotto et al., 2017). The CNA profiles of 24 single cells from
each genotype (WT+EGFP, WT+Her2, Mre11ATLD+EGFP, and
Mre11ATLD+Her2) are depicted as a clustered heatmap, with
the total fraction of altered genome for each cell shown on
the right as a bar graph (Figure 1B). Significantly, WT pMMECs
expressing EGFP had very few CNAs, corroborating the
low level of background signal associated with the scWGS
methodology and analysis pipeline employed in this study. In
contrast, there is a substantial increase in the fraction of genome
altered per cell after both Her2 expression and Mre11 perturba-
tion (Figure 1B, bar graph on right). Unsupervised clustering was
also performed but did not reveal any clonally related individual
cells (Figure 1B), which is consistent with the relatively short time
period after transduction when the cells were analyzed. Although
the majority of the observed CNAs are non-recurrent and thus
are indicative of a sporadic etiology, there are some focal
CNAs that were recurrently seen in multiple cells within the
same genotype. An interesting example is a focal region in chro-
mosome 1 (boxed region in Figure S1) that has increased ploidy
in 4/24WT+Her2 pMMECs and 5/24Mre11ATLD+Her2 pMMECs,
but not in the other genotypes analyzed. This minimal region of
CNA overlap contains Parp1, which is instrumental for single-
strand break repair (Ray Chaudhuri and Nussenzweig, 2017)
and is frequently overexpressed in human HER2+ breast can-
cers (Stanley et al., 2015). Furthermore, a recent study suggests
that Parp1 activity reduces the rate of replication fork progres-









































































Figure 1. Oncogene Expression Rapidly Induces Copy Number Aberrations in Individual pMMECs
(A) Schematic representation of the single-cell, whole-genome sequencing process. WT or Mre11ATLD pMMECs were transduced with EGFP or Her2-EGFP.
Growth curves on an irradiated feeder layer are shown. The mean of three biological replicates is shown with error bars depicting the standard error of the mean
(SEM). ***p < 0.001, calculated using a two-tailed t test on log transformed day 14 data. On day 14, fluorescence-activated cell sorting (FACS) was performed to
sort single EGFP+ cells into a 96-well microtiter plate. These cells were then processed for sequencing as described in the methods.
(B) Heatmap showing copy number of individual segments for each cell. The individual cells are clustered by geometric distance, which does not reveal any clonal
relationships. The histograms at the right show the total fraction of aberrant genome per cell. p values were calculated by two-tailed Mann-Whitney test. ****p <
0.0001; *p < 0.05.
See also Figure S1.studies, our findings are suggestive that Parp1 copy number
gains may confer a growth advantage in the setting of Her2-
induced mammary preneoplasia.
Mre11 Dysfunction Results in a Copy Number Loss
Phenotype
We observed a significant increase in CNAs per cell after Her2
expression in both WT and Mre11ATLD pMMECs (Figure 2A),
indicating that oncogenic stress stimulates CIN early in
neoplasia and does not require DDR deficiency. In fact, we did
not observe an increase in CNAs per cell inMre11ATLD pMMECs
expressing Her2, suggesting that oncogene expression is the
major driver of CNA development in this model. Consistentwith a role for Mre11 in suppressing spontaneous genomic
instability, Mre11ATLD pMMECs expressing EGFP also had a
modest increase in CNAs compared to the respective WT
control (Figure 2A). We next evaluated the size distribution of
observed CNAs in the different genotypes. Notably, the
CNA size distributions in both EGFP and Her2-expressing
Mre11ATLD pMMECs were significantly larger than the CNA
size distribution observed in WT+Her2 pMMECs (Figure 2B).
This difference was even more striking when evaluating CNAs
that give rise to genomic gains versus losses. Although the
size distribution of CNA gains and losses (%5,000 kb) was equiv-
alent in theWT pMMEC genotypes, we observed a highly signif-



































































































































































































































































Figure 2. Mre11 Dysfunction Alters the Profile of Copy Number Aberrations to Favor Genomic Loss
(A) Scatterplot showing total aberrations per cell in the different genotypes of pMMECs (mean ± SEM). **p < 0.01; ****p < 0.0001 by two-tailedMann-Whitney test.
(B) Violin plots depicting the size distribution of aberrant copy number regions in each cell type. The line represents the median value. ***p < 0.001; ****p < 0.0001
by two-tailed Mann-Whitney test.
(C) Scatterplot CNA segment size for deletions and insertions, demonstrating a bias toward genomic deletions inMre11ATLD genotypes. Error bars are median ±
95% confidence level. ****p < 0.0001 by two-tailed Mann-Whitney test.
(D) Cumulative size distribution CNA deletions and insertions for WT+EGFP (green), WT+Her2 (purple), Mre11ATLD+EGFP (blue), and Mre11ATLD+Her2 (red)
pMMECs.
(E) Breakpoint regions in Mre11ATLD+Her2 cells are associated with the largest genes (>300 kb). Violin plots show an empirical null distribution of overlaps
generated by shuffle permutation of the observed CNA data, as described in the methods. Black line in violin plots is the median value, and the black dot is the
observed value. p values are approximated from the empirical null distribution. *p = 0.03–0.05; **p = 0.01–0.03; ***p < 0.01.
(F) Expression of Her2 increases the number of R-loop DNA-RNA hybrids, detected by S9.6 immunofluorescence staining ofWT pMMECs transducedwith EGFP
control or Her2. Scatterplot of the number of S9.6 foci per nucleus in control and Her2-expressing cells is shown. On the right are representative images of S9.6
nuclear foci used to generate the scatterplot. ****p < 0.0001 using a two-tailed t test. Scale bar represents 5 mm.
See also Figure S2.in both EGFP and Her2-expressing Mre11ATLD pMMECs (Fig-
ure 2C). The enrichment for genomic loss CNAs in Mre11ATLD
pMMECs is also visually evident in the scWGS heatmaps
shown in Figure 1B. To better characterize the relationship be-
tween CNA size and the observed enrichment for genomic
losses, we plotted the cumulative frequency distribution of
CNA gains and losses according to individual aberration size
(Figure 2D). This analysis demonstrated that the enrichment
for genomic loss was evident for CNAs larger than 1,000 kb in
Mre11ATLD+EGFP cells and for CNAs greater than 500 kb in
Mre11ATLD+Her2 cells. In contrast, no enrichment for CNA losses
was observed in WT+Her2 pMMECs. The enrichment for
genomic losses in the setting of Mre11 hypomorphism is remi-
niscent of copy number losses that result from accumulation
of under-replicated DNA (UR-DNA) in settings of elevated repli-
cation fork stress in other model organisms (Salim et al., 2017;
Yarosh and Spradling, 2014). Thus, our findings are consistent
with replication fork instability caused by Mre11 dysfunction in1388 Cell Reports 30, 1385–1399, February 4, 2020the setting of oncogenic stress, resulting in an accumulation of
UR-DNA. Furthermore, because copy number losses are one
mechanism by which loss of heterozygosity (LOH) in cancer
may arise, an enrichment for larger sized deletions inMre11ATLD
pMMECs may be consistent with the high levels of LOH that are
observed in human breast and ovarian cancers with homologous
recombination deficiency (Wang et al., 2012).
Chromosomal Aberrations Are Associated with Large
Genes
Next, we investigated whether there were any distinguishing
features of the genomic regions where the oncogene-induced
CNAs were observed. The sparseness of our scWGS data pre-
cluded single-base-pair resolution of CNA breakpoints. In
contrast, we approximated the genomic region of the chromo-
somal aberration breakpoint as contained within the two
genomic bins that span the transition in copy number (Fig-
ure S2A; STAR Methods). We next evaluated whether these
breakpoint-containing regions were enriched in previously anno-
tated genomic features and used a shuffle permutation of the
observed CNA profiles for each of the genotypes as a
means of establishing statistical significance of the enrichment
(Supplemental Methods). We did not observe any significant
enrichment or depletion of satellite, simple repeat, long terminal
repeats (LTRs), long interspersed nuclear elements (LINEs),
short interspersed nuclear elements (SINEs), or CpG island
sequences among the breakpoint regions for any of the
genotypes (Figure S2B). In contrast, there was significant
enrichment of breakpoint-containing regions with genes. Genes
were further subdivided according to size into four bins of <50
kb, 50–150 kb, 150–300 kb, and >300 kb. There was a
significant enrichment of chromosomal breakpoint regions
within large genes (>300 kb) relative to random chance for
Her2-expressing Mre11ATLD pMMECs (Figure 2E). In contrast,
chromosomal breakpoint regions in WT+Her2 pMMECs were
relatively enriched in moderately sized genes between 50 kb
and 300 kb. Large genes are known to take longer than one
cell cycle to transcribe and have been associated with R-loops,
chromosomal fragile sites, and recurrent deletions in many
cancers (Glover et al., 2017; Helmrich et al., 2006, 2011; Le
Tallec et al., 2013; Wilson et al., 2015). Recent work has also
demonstrated an increase in transcription-replication conflicts
(TRCs) upon oncogene expression (Macheret and Halazonetis,
2018), which may be due to greater transcriptional activity
and/or persistence of R-loops (Kotsantis et al., 2016). We
thereby assessed global R-loop levels in our pMMEC model
using immunofluorescence with the monoclonal S9.6 antibody
and observed a significant increase in R-loops 3 days after
transduction with lentivirus expressing Her2-EGFP in pMMECs,
relative to control pMMECs transduced with EGFP alone
(Figure 2F). Collectively, these findings indicate that oncogenic
stress in early mammary neoplasia stimulates R-loop expres-
sion and CNAs enriched in large genes, which in the setting of
Mre11 dysfunction becomes strongly enriched in a copy number
loss phenotype.
Mre11 Suppresses Oncogenic Proliferation
Independently of p53 and ATM
Wenext investigated the effect ofMre11 hypomorphism in trans-
genic mammary hyperplasia models induced by c-Myc (Myc)
overexpression,Rb1 deletion, and/or Trp53 deficiency—genetic
aberrations that are prevalent in human TNBCs and basal-like
breast cancer (Cancer Genome Atlas, N. and Cancer Genome
Atlas Network, 2012). Because the Mre11ATLD allele is a
premature stop codon in the C-terminal region of Mre11, we hy-
pothesized that a comparable hypomorphic allele could be
generated using CRISPR/Cas9 gene targeting in pMMECs, as
has previously been demonstrated in murine embryonic
fibroblast cell lines (Wyatt et al., 2016). pMMECs isolated from
Rosa26LSL-Cas9-EGFP (abbreviated R26Cas9) mice (Platt et al.,
2014) were transduced with lentivirus expressing Cre recombi-
nase and single guide RNA (sgRNA) targeting the C-terminal re-
gion of Mre11 (Cre-sgMre11) or a control non-coding region on
chromosome 2 (Cre-sgControl; Figures 3A and 3B). Effective
target site mutagenesis was confirmed by Sanger sequencing
of 10 cloned amplicons each fromR26Cas9 pMMECs transducedwith Cre-sgControl or Cre-sgMre11 (Figure S3A). CRISPR-
directed mutations corresponding to the expressed sgRNA
were identified, which resulted in an Mre11 frameshift mutation
in all 10 clones analyzed from sgMre11-transduced pMMECs
(Figure S3A). Furthermore, pMMECs transduced with Cre-
sgMre11 had reduced expression of Mre11 (Figure S3B), pheno-
copying the destabilizing effect of theMre11ATLD allele onMre11
complex protein stability (Theunissen et al., 2003) These findings
validated the pMMEC platform to evaluate phenotypes associ-
ated with oncogene expression and/or Mre11 hypomorphism.
We next interbred the R26Cas9 mice with transgenic mice
containing a Cre-inducible Myc overexpression cassette also
at the Rosa26 locus (Rosa26LSL-MycOE-hCD2 or R26Myc) to
generate combination transgenic R26Myc/Cas9 mice (Figures
3A and 3B). pMMECs derived from these mice were trans-
duced with lentivirus expressing Cre recombinase and either
sgControl or sgMre11, revealing greater Myc-induced prolifer-
ation in cells with a hypomorphic Mre11 complex (Figure 3C).
Notably, expression of Cre-sgMre11 in R26Cas9/Cas9 pMMECs
did not result in a substantial increase in proliferation, indi-
cating that this anti-proliferative effect of Mre11 is oncogene
specific.
To investigate whether suppression of oncogene-induced
proliferation by the Mre11 complex is p53 dependent, we
generated R26Myc/Cas9; Trp53fl/fl mice. Cre recombinase
expression in pMMECs isolated from these mice induces
deletion of Trp53 exon 2 in conjunction with activated expres-
sion of Cas9 and Myc (Figures 3B and S3). Mre11 complex
hypomorphism induced by expressing Cre recombinase and
sgMre11 resulted in significantly increased proliferation rela-
tive to the R26Myc/Cas9; Trp53fl/fl pMMECs transduced with
Cre and sgControl (Figure 3D). We also generated and
analyzed R26Cas9Trp53fl/flRb1fl/fl mice, representing another
model of human TNBC (Figure 3B; Cancer Genome Atlas, N.
and Cancer Genome Atlas Network, 2012; Jiang et al., 2010;
Jonkers et al., 2001). Once again, R26Cas9Trp53fl/flRb1fl/fl
pMMECs transduced with Cre recombinase and sgMre11
demonstrated significantly increased proliferation relative to
cells expressing sgControl (Figure 3D). These findings strongly
argue that Mre11-mediated suppression of oncogenic
proliferation is p53 independent. Given that the Mre11 com-
plex has both ATM-dependent and independent effects in
the response to DNA damage and replication stress (Rein
and Stracker, 2014), we sought to determine the ATM depen-
dency of Mre11-mediated suppression of oncogenic prolifera-
tion. R26Cas9Trp53fl/flRb1fl/fl pMMECs were transduced with
either sgControl or sgMre11 and then treated with ATM
inhibitor Ku55933 or vehicle control. ATM inhibition (Fig-
ure S3D) did not increase proliferation of Rb1/Trp53/
pMMECs (Figure 3E). A possible explanation for these obser-
vations is that growth suppression by ATM is p53 dependent,
consistent with emerging clinical evidence that ATM and TP53
may be epistatic in breast cancer (Weigelt et al., 2018).
Conversely, Mre11 hypomorphism stimulated oncogenic
proliferation irrespective of ATM inhibition (Figure 3E). These
observations collectively indicate that Mre11-mediated sup-
pression of oncogenic proliferation is both p53 and ATM
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Figure 3. Mre11 Suppresses Oncogenic Proliferation in pMMECs Independently of Trp53 and ATM
(A) Graphic representing how pMMECs are harvested from the mice and manipulated in vitro to assess growth rates.
(B) Description of compound transgenic mice used for pMMEC experiments and resulting genotypes after introduction of Cre recombinase.
(C) pMMEC growth curves examining the effect of Myc overexpression and/orMre11 hypomorphic mutation. Cell counts are normalized to their respective day
0 counts.
(D) Significant effect of Mre11 mutation on oncogenic growth induced by Myc overexpression or Rb1 deletion in p53-deficient pMMECs. Cell counts are
normalized to their respective day 0 counts.
(E) ATM inhibitor Ku55933 does not phenocopy the growth-stimulating effects ofMre11mutation in Rb1/Trp53/ pMMECs. Statistical significance in (C)–(E)
was determined by two-tailed t test on log-transformed data comparing day 12. The p values were adjusted for multiple comparisons by the method of Holm-
Sidak. Data are represented as mean ± SEM.
See also Figure S3.Mre11 Suppresses Oncogene-Induced R-Loops and
DNA Damage
The Mre11 complex suppresses the accumulation of sponta-
neous, replication-associated DSBs (Oh and Symington, 2018).
In contrast, some studies have demonstrated that Mre11
nuclease activity can also promote destabilization of stalled
replication forks (Malacaria et al., 2019; Schlacher et al., 2011).
To determine whether Mre11 promotes or suppresses onco-
gene-induced DSBs in pMMECs, we measured gH2AX foci,
53BP1 foci, and neutral COMET tails (Figures 4A, 4B, and
S4A). Mre11 hypomorphism induced by CRISPR/Cas9-medi-
ated targeting of Mre11 resulted in significantly higher levels
of nuclear DSBs in both p53-proficient and p53-deficient
pMMEC models. Similarly, Mre11 hypomorphism increased
the levels of single-stranded DNA damage, as measured by
pRPA2 immunofluorescence and alkaline COMET assay (Fig-
ures 4B and S4B). The increase in pRPA2 foci was most
significant in cells that were no longer in S phase (Figure S4C),
indicative of a deficiency in resolution/repair of replication
stress in Mre11 mutant pMMECs. These findings argue that
Mre11 suppresses the accumulation of oncogenic DNA damage
(single-stranded breaks and DSBs) in both p53-proficient and
p53-deficient models of mammary preneoplasia.
Due to our prior finding that oncogenic stress in the setting of
Mre11 hypomorphism induces copy number aberrations in
genomic regions known to have high levels of R-loops (see Fig-1390 Cell Reports 30, 1385–1399, February 4, 2020ure 2E), we assessed global R-loop levels using S9.6 immunoflu-
orescence. As previously demonstrated with Her2 expression
(see Figure 2F), we again found that oncogenic stress stimulates
R-loop foci in both R26Myc and R26Cas9Rb1/Trp53/
pMMECs (Figure 4C). Significantly, we also found R-loop levels
increased substantially further upon Mre11 dysfunction, in both
p53-proficient and p53-deficient models (Figure 4C). These ob-
servations are consistent with a recent study implicating
the Mre11 complex as a critical mediator of transcription-repli-
cation conflicts in yeast and mammals (Chang et al., 2019). To
establish whether the increase in R-loops mediates the
increased levels of oncogenic DNA damage in pMMECs with
hypomorphic Mre11, we modified our Cre-sgControl/sgMre11
lentiviral construct to also co-overexpress RNase H1 (Fig-
ure S4D). As expected, co-overexpression of RNase H1
abolished the increase in R-loops observed in the setting of
hypomorphic Mre11 (Figure 4D). RNase H1 expression also
rescued the increase in oncogenic DSBs and single-stranded
DNA breaks induced by Mre11 dysfunction (Figures 4E and
4F). These findings were also confirmed by neutral and
alkaline COMET assays (Figures S4E and S4F). Thus, an aber-
rant accumulation of R-loops in pMMECs with Mre11 dysfunc-
tion is necessary for the observed increase in oncogenic DNA
damage. Collectively, these findings support a model wherein
Mre11 mitigates DNA damage incurred at sites of oncogene-
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Mre11-Deficient Mammary Tumors Have Increased R-
Loops and a Genomic Loss Phenotype
To extend and validate these results in vivo, R26Cas9Rb1fl/
flTrp53fl/fl and R26Myc/Cas9 female mice were administered
intraductal injections of lentivirus expressing Cre-sgControl or
Cre-sgMre11 into mammary gland 4. Two weeks after injection,
the mice were euthanized and gland 4 (injected) and gland 5
(uninjected control) were processed for histopathology. There
was a qualitative (Figure 5A) and quantitative (Figure 5B) in-
crease in mammary epithelial hyperplasia after intraductal
injection with Cre-sgMre11, relative to glands injected with
Cre-sgControl. Thus, Mre11 suppresses oncogenic hyperplasia
in vivo in response to diverse oncogenic drivers and in the setting
of induced p53 deficiency.
Cohorts of Cre-sgControl and Cre-sgMre11-injected
R26Cas9Rb1fl/flTrp53fl/fl mice were monitored for mammary tu-
mor development. Tumor initiation frequency was higher in
glands injected with Cre-sgMre11 (70%) versus Cre-sgControl
(50%), and there was a trend toward a shorter latency
period (Figure 5C). Tumor-free survival rates, however, did not
achieve statistical significance (p = 0.052), suggesting that
tumor latency in the R26Cas9Rb1fl/flTrp53fl/fl model may also be
dependent on the stochastic acquisition of secondary genetic
events. Mammary tumor lines were established from the
induced tumors, and as expected, expression of the entire
Mre11 complex (Mre11, Rad50, and Nbs1) was substantially
reduced in tumors derived from mice injected with Cre-sgMre11
(Figure 5D). Consistent with our observations with pMMECs,
sgMre11 mammary tumor lines had a higher proliferation rate
(Figure 5E) and significantly higher levels of R-loops (Figure 5F)
relative to sgControl mammary tumor lines.
We also performed matched tumor-normal whole-genome
sequencing (253 mean depth of coverage) of three Cre-
sgControl and three Cre-sgMre11-induced mammary tumors
in R26Cas9Rb1fl/flTrp53fl/fl mice. Site-specific mutagenesis of
the Mre11 locus was confirmed in all of the Cre-sgMre11 mam-
mary tumors (data not shown). Single-nucleotide variant muta-
tion signatures were not statistically different between the Cre-
sgControl and Cre-sgMre11 tumors (Figure S5). Notably, there
was no increase in COSMIC signature 3, which has been associ-
ated with homologous-recombination-deficient cancers (Alex-
androv et al., 2013; Riaz et al., 2017; Rosenthal et al., 2016). A
similar lack of COSMIC signature 3 enrichment has beenFigure 4. Mre11 Suppresses Oncogene-Induced DNA Damage and R-L
(A) Mre11 suppresses oncogene-induced gH2AX foci formation in both p53-p
percent of nuclei containing R5 gH2AX foci in the different genotypes. Represen
indicates 5 mm.
(B) Bar graphs depicting the fold change in tail DNA percent for both alkaline (left)
Cre-sgRNA transduction. Representative images of alkaline and neutral COME
pMMECs are shown. Data are represented as mean ± SEM.
(C) Mre11 suppresses oncogene-induced R-loop formation independently of Trp5
the genetic backgrounds shown after transduction with Cre-sgControl versus Cre
shown. White bar indicates 5 mm.
(D) S9.6 (R-loop) foci after RNase H1 overexpression in R26Cas9Rb1fl/flTrp53fl/fl p
(E and F) Additionally, RNase H1 overexpression counteracts the increase in (E) g
pMMECs.
***p < 0.001; ****p < 0.0001. p values are calculated using a two-tailed Mann-Wh
See also Figure S4.
1392 Cell Reports 30, 1385–1399, February 4, 2020observed in human breast cancers with ATM deficiency (Weigelt
et al., 2018). Structural variants (SVs) were observed in both
sgControl and Cre-sgMre11 Rb1/Trp53/ mammary tumors
(Figure 5G). Significantly, the observed SVs in Mre11 hypomor-
phic tumors were highly enriched for deletions relative to control
tumors (Figures 5G and 5H). Thus, the genomic loss phenotype
observed in early oncogenic hyperplasia induced in the setting of
Mre11 hypomorphism (see Figures 2C and 2D) is also preserved
upon tumorigenesis in a distinct p53-deficient breast cancer
model. These observations indicate that Mre11 complex
dysfunction is causative for a genomic scar phenotype consist-
ing of an enrichment for copy number losses/genomic deletions.
Breast Cancers with Mre11 Dysfunction Are
Hypersensitive to DNA-Damaging Therapy and
Inhibitors of ATR and PARP
Our finding that the Mre11 complex has p53-independent, tu-
mor-suppressive functions leads to a hypothesis that Mre11
complex dysfunction may be selected for in p53-deficient breast
cancers. Indeed, a prior study has demonstrated downregula-
tion of Mre11 complex proteins in TNBC (Bartkova et al.,
2008), 90% of which harbor p53 pathway deficiency (Cancer
Genome Atlas, N. and Cancer Genome Atlas Network, 2012).
To validate these findings, we performed immunohistochemistry
for Mre11 and Nbs1 on a tissue microarray of 254 early-stage
TNBCs that were treated at Memorial Sloan Kettering Cancer
Center. Ninety-three percent of the patients received adjuvant
chemotherapy. We identified 23 samples (9%) with less than
10% of tumor nuclei staining for Mre11 or Nbs1 protein, while
infiltrating stromal cells retained normal expression (Figure 6A).
Notably, we found that all tumors with low Mre11 expression
also had low Nbs1 expression, consistent with underexpression
or destabilization of the Mre11 complex. The lack of immunore-
activity for Mre11 and Nbs1 was also confirmed on whole
tissue sections from the original tumor blocks. These ‘‘Mre11
complex low’’ cancers presented with similar T- and N- stage
at presentation relative to cancers with normal Mre11 complex
expression (Figure S6). Notably, patients with Mre11 complex
low TNBC had a significantly better breast-cancer-specific sur-
vival compared to the remainder of TNBCs with normal Mre11
complex expression (Figure 6B).
Because disease-free survival of patients with TNBC is
highly associated with improved chemotherapeutic responsesoops in p53-Proficient and p53-Deficient Models
roficient and p53-deficient pMMECs. Bar graphs show quantification of the
tative images (right) of the nuclei containing gH2AX foci are shown. White bar
and neutral (right) COMET assays in pMMECs with the genotypes shown post-
Ts in R26Cas9+sgControl, R26Cas9/Myc+sgControl, and R26Cas9/Myc+sgMre11
3. Scatterplot shows a quantification of the nuclear S9.6 foci in pMMECs from
-sgMre11. Representative images (right) of the nuclei containing S9.6 foci are
MMECs transduced with Cre-sgControl or Cre-sgMre11.
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Figure 5. Cell Proliferation, R-Loops, andGenomic Loss SignatureAre Elevated inRb1/Trp53/Mammary Tumors EngineeredwithMre11
Hypomorphism
(A) Representative images of mammary hyperplasia 2 weeks after intraductal injection of R26Cas9Rb1fl/flTrp53fl/fl or R26Cas9/Myc mice with Cre-sgControl or Cre-
sgMre11-expressing lentivirus.
(B) Quantification of mammary hyperplasia in R26Cas9Rb1fl/flTrp53fl/fl mice as shown in (A). The fifth, non-injected, mammary gland serves as a negative control.
Data are represented as mean ± SEM. Significance was determined using two-tailed Mann-Whitney test.
(C) Kaplan-Meier tumor-free survival plot of R26Cas9Rb1fl/flTrp53fl/fl mice after mammary intraductal injection of either Cre-sgControl or Cre-sgMre11 lentivirus.
p value was calculated using a two-tailed Gehan-Breslow-Wilcoxon test.
(D) Mre11, Rad50, and Nbs1 protein levels in tumors frommice in (C), validating protein destabilization induced by CRISPR/Cas9-mediated Mre11 mutagenesis.
(legend continued on next page)
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(Cortazar et al., 2014), we hypothesized that Mre11 hypomor-
phism may promote hypersensitivity to DNA-damaging
therapeutics in breast cancer. To directly address this
possibility, we used breast tumor lines derived from
R26Cas9Trp53fl/flRb1fl/fl mice injected with Cre-sgControl or
Cre-sgMre11 to evaluate the effect of Mre11 hypomorphism
on sensitivity to DNA-damaging therapeutics. We found that
breast cancer cells expressing hypomorphic Mre11 were
hypersensitive to several DNA-damaging therapeutics
commonly used to treat breast cancer, but not to the anti-micro-
tubule agent Taxol (Figure 6C). We also evaluated the sensitivity
of these mammary tumor lines to inhibitors of ATR (VE-821) and
PARP (BMN-673), particularly because both of these pathways
are components of the replication stress response and the
ATR pathway has been implicated in resolution of R-loops
(Cristini et al., 2018; Hodroj et al., 2017; Nguyen et al., 2018).
We observed significantly greater hypersensitivity of Mre11
hypomorphic Rb1/Trp53/ breast tumor lines to both VE-
821 and BMN-673, relative to control Rb1/Trp53/ breast tu-
mor lines (Figure 6D). Collectively, these findings indicate that
Mre11 complex dysfunction is evident in a subset of TNBC pa-
tients and associated with improved clinical outcomes after
DNA-directed cancer therapy.
DISCUSSION
Seminal studies (Bartkova et al., 2005, 2006; Di Micco et al.,
2006; Gupta et al., 2013; Halazonetis et al., 2008) have
described an Mre11-dependent DDR activated by oncogene-
induced replication stress in preneoplasia that mediates phys-
iologically significant tumor suppression. Some of these studies
have claimed that the oncogene-induced DDR exerts these ef-
fects primarily through p53 activation. To our knowledge, ours
is the first study to directly assess the effects of DDR perturba-
tion in p53-deficient models of oncogenic preneoplasia. We
demonstrate that Mre11-mediated suppression of oncogenic
proliferation, DNA damage, and genome instability are p53 in-
dependent. Thus, our findings challenge current models of the
oncogene-induced DDR and its relation to p53: rather than be-
ing epistatic to p53, the Mre11-dependent DDR mediates p53-
independent effects that regulate oncogenic phenotypes,
including proliferation, genome instability, and therapeutic
sensitivity.
Single-cell, whole-genome sequencing of premalignant mam-
mary epithelial cells revealed important clues into the critical
functions of the Mre11-dependent DDR in response to onco-(E) Cells from the sgMre11 tumors grow faster in vitro than cells from the sgContro
curves were acquired using the Incucyte Live Cell Analysis system. Data are rep
(F) Cells from sgMre11-derived tumors have more R-loops than cells from sgCont
immunofluorescence using the S9.6 antibody. Data are represented as mean ±
Whitney test.
(G) Representative circos plot of structural variations identified by whole-genome
R26Cas9Rb1fl/flTrp53fl/fl model. Purple lines indicate translocations between differ
(H) Analysis of structural aberrations identified from tumor-normal WGS fro
R26Cas9Rb1fl/flTrp53fl/flmodel. Deletions (>50 bp) are highly over-represented inM
mean ± SEM. Q value was estimated using a two-tailed t test with false discove
statistically significant (i.e., Q < 0.05).
See also Figure S5.
1394 Cell Reports 30, 1385–1399, February 4, 2020genic stress. We found that oncogene expression was sufficient
to rapidly induce widespread CNAs in otherwise completely
normal primary mammary epithelial cells, independently of
Mre11 status. Recent genomic analyses of human breast pre-
neoplasia have also suggested an early origin of chromosomal
instability, which does not seem to require DDR deficiency (Mar-
telotto et al., 2017; Rane et al., 2015). In the setting of Mre11
dysfunction, we observed a striking enrichment in genomic los-
ses rather than gains, which was further exacerbated by onco-
gene expression. A similar enrichment in genomic deletions
was seen in Rb1/Trp53/ mammary tumors engineered to
express hypomorphic Mre11 alleles, indicating that this genomic
scar signature of Mre11 dysfunction persists during tumorigen-
esis. A possible explanation for the observed enrichment in
genomic losses may be the accumulation of UR-DNA in onco-
gene-expressing cells with Mre11 dysfunction. Coupled with
the observation that Mre11 dysfunction results in higher levels
of unrepaired oncogene-induced DSBs, the increased levels of
UR-DNA in this setting may be due to a higher rate of replication
fork collapse (Figure 7).
The location of oncogene-induced chromosomal aberrations
in the setting of Mre11 dysfunction were non-randomly distrib-
uted and significantly enriched in large genes (>300 kb). These
genomic regions are known to be occupied by R-loops, depleted
in replication origins, and associated with chromosomal fragility
(Helmrich et al., 2011). Thus, our findings reinforce prior reports
of fragile site instability induced by oncogenic stress (Miron et al.,
2015) and complement the recent demonstration of oncogene-
induced TRCs that stimulate intragenic dormant origin firing (Ma-
cheret and Halazonetis, 2018). Our results suggest that Mre11
promotes replication fork stability at oncogene-induced TRCs
(Figure 7). R-loops can either be persistent structures that are
stabilized by DNA secondary structure or transient intermediates
of gene transcription. Further work to determine whether one of
these types of R-loops is a greater contributor to oncogene-
induced CIN is warranted. We observed a striking increase in
R-loop expression in mammary hyperplasias and tumors
with Mre11 dysfunction. Mitigation of R-loops by RNase H1
expression in Mre11 hypomorphic cells diminished oncogenic
DNA damage. A causative role for R-loops in the etiology of
oncogenic DNA damage can be explained in the setting of repli-
cation fork collisions, which can give rise to fork uncoupling
and/or collapse. Thus, our findings support a model wherein
the Mre11 complex has critical functions in mitigating DNA dam-
age at TRCs in oncogene-expressing cells (Figure 7). Similar
conclusions were drawn in a recent analysis of yeast and humanl tumors. Three independent tumor lines are shown for each genotype. Growth
resented as mean ± SEM.
rol tumors. Three independent tumor lines of each genotype were evaluated by
standard deviation. Significance was determined using a two-tailed Mann-
sequencing ofWT or Mre11 hypomorphic mammary tumors derived from the
ent chromosomes. Blue lines indicate intra-chromosomal rearrangements.
m three WT and three Mre11 hypomorphic mammary tumors from the
re11 hypomorphicRb1/Trp53/mammary tumors. Data are represented as
ry rate correction using Graphpad Prism v8. All other comparisons were not
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Figure 6. Favorable Clinical Outcomes and Therapeutic Vulnerabilities of Mre11 Hypomorphic p53-Deficient Breast Cancers
(A) Immunohistochemistry for (1) Mre11 and (2) Nbs1 performed on tissue microarrays of primary triple-negative breast cancers (n = 254). In both cases (1 and 2),
the left panel represents an example of a ‘‘normal’’ expressor and the right case represents an example of a ‘‘low’’ expressing tumor.
(B) Kaplan-Meier breast-cancer-specific survival of patients with TNBC that had normal expression of Mre11 and Nbs1 or patients with TNBC that had low
expression of both Mre11 and Nbs1 (i.e., Mre11 complex low). p value was calculated by a two-tailed log rank test.
(C) In vitro sensitivity of sgControl and sgMre11 Rb1/Trp53/ mammary tumor lines treated with the indicated doses of cisplatin, doxorubicin, camptothecin,
and Taxol. Percent confluence was measured using an Incucyte Live-Cell Analysis System 7 days after drug exposure.
(D) Similar drug sensitivity assays using the ATR inhibitor VE-821 and PARP inhibitor BMN-673. The data shown represent the average of at least two independent
cell lines for each genotype with three replicates each. Significance was determined using a two-tailed t test at the highest drug dosage. Data are represented as
mean ± SEM.
See also Figure S6.cell linemodels (Chang et al., 2019). Amore detailed examination
of how the Mre11 complex promotes genome integrity at
TRCs—particularly in consideration of head-on versus co-
directional collisions (Hamperl et al., 2017)—may provide addi-
tional clues regarding the etiology of genome instability during
tumorigenesis.
The observation that Mre11 mutant cells have increased pro-
liferation despite elevated levels of unrepaired DNA damage
points to an oncogene-induced DNA damage checkpoint that
is mediated by Mre11. The nature of the Mre11-mediated
checkpoint in response to oncogenic stress remains to be further
elucidated. Our finding that this checkpoint remains operativein p53-deficient cells suggests a possible role for an Mre11-
mediated G2/M checkpoint in response to oncogenic stress.
We found that ATM inhibition, however, did not phenocopy the
effect of Mre11 hypomorphism in promoting oncogenic prolifer-
ation, suggesting that non-canonical mechanisms may also be
involved.
Reduced expression of Mre11 complex proteins has been
identified in a variety of human malignancies (Bartkova et al.,
2008; Brandt et al., 2017). Our data provide direct evidence
supporting a role for Mre11 in mediating resistance to
DNA-damaging therapy as well as PARP and ATR inhibitors
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Figure 7. Model Depicting Genome Stabilizing Functions of Mre11 at Oncogene-Induced Transcription-Replication Conflicts
Mre11 dysfunction during oncogenic breast neoplasia results in accumulation of R-loops, replication-associated DSBs, under-replicated DNA, an enrichment of
genomic deletions, and uncontrolled proliferation. See the Discussion for further details.associated with improved clinical outcomes in a cohort of
TNBC patients who were treated with adjuvant chemotherapy.
The finding that these cancers may also be hypersensitive to
targeted DDR pathway inhibitors represents opportunities for
targeted therapy that may reduce the need for highly toxic
combination chemotherapeutic regimens in a subset of
TNBC patients.
The Mre11-dependent DNA damage response is evolution-
arily more primitive than p53 and functions as a mechanism to
preserve genome integrity in response to endogenous and
exogenous genotoxic stresses. The observation that DDR
gene perturbations are prevalent across many human cancer
types (Knijnenburg et al., 2018) suggests that aspects of the
DDR are also tumor suppressive. Our findings reveal a p53-in-
dependent checkpoint function of the Mre11 complex that sup-
presses genome instability and uncontrolled proliferation
induced by oncogenic mutations. Disruption of this genome
integrity checkpoint may drive the catastrophic loss of
chromosomal stability that is observed in a variety of clinically
aggressive cancers. Elucidating additional mediators of this
tumor-suppressive pathway may reveal new opportunities for1396 Cell Reports 30, 1385–1399, February 4, 2020personalized therapy of human cancers, including those with
p53 deficiency.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d LEAD CONTACT AND MATERIALS AVAILABILITY
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Cell Lines
B Primary Murine Mammary Epithelial Cells (pMMECs)







B Viral production and infection
B Chemotherapeutic and inhibitor sensitivity assays
B Automated analysis of mouse mammary tissues
B Human breast cancer tissue microarrays
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Single cell whole genome sequencing
B Quantification and statistical analysis
B Statistical significance of breakpoint region intersects
B Tumor whole genome sequencing
B Statistical Analyses
d DATA AND CODE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
celrep.2020.01.020.
ACKNOWLEDGMENTS
We thank Christine E. Foster, Bentley R. Midkiff, Muzaffar Akram, and Brian
Cooley and the UNC Animal Surgery Core Lab for their expert technical assis-
tance and members of the Gupta laboratory for advice and support. G.P.G.
holds a Career Award for Medical Scientists from the Burroughs Wellcome
Fund. This work was supported by Susan G. Komen CCR16377075
(G.P.G.), NCI R37 CA227837 (G.P.G.), NIH GM59413 and NCI CA087497
(J.H.J.P.), the UNC-Lineberger Cancer Center core grant (P30 CA016086),
theMSKCancer Center core grant (P30 CA008748), and the University Cancer
Research Fund. J.S.R.-F. is funded in part by the Breast Cancer Research
Foundation. The UNC Translational Pathology Laboratory is supported in
part by grants from the NCI (5P30CA016086-42), NIH (U54-CA156733), NIEHS
(5 P30 ES010126-17), UCRF, and NCBT (2015-IDG-1007). K.D.F.-S. is funded
by Ruth L. Kirschstein National Research Service Award (NRSA) Individual
Postdoctoral Fellowship (Parent F32) (F32 CA 206345). The UNC Flow Cytom-
etry Core Facility is supported in part by P30 CA016086 Cancer Center Core
Support Grant to the UNC Lineberger Comprehensive Cancer Center, by the
North Carolina Biotech Center Institutional Support Grant 2017-IDG-1025,
and by the National Institutes of Health 1UM2AI30836-01. The Microscopy
Services Laboratory is supported in part by P30 CA016086 Cancer Center
Core Support Grant to the UNC Lineberger Comprehensive Cancer Center.
The UNC Translational Pathology Laboratory is supported in part by grants
from the NCI (5P30CA016086-42), NIH (U54-CA156733), NIEHS (5 P30
ES010126-17), UCRF, and NCBT (2015-IDG-1007).
AUTHOR CONTRIBUTIONS
Conceptualization, G.P.G. and J.H.J.P.; Methodology, G.P.G.; Software,
D.A.S. and L.E.M.; Formal Analysis, D.A.S. and N.U.R.; Investigation, K.D.F.-
S., D.A.S., R.J.K., L.G.M., and Y.H.W.; Resources, G.P.G., A.Y.H., S.N.P.,
J.S.P., J.S.R.-F., and J.H.J.P.; Writing – Original Draft, G.P.G., K.D.F.-S. and
D.A.S.; Writing – Review & Editing, all authors; Funding Acquisition, G.P.G.,
K.D.F.-S., and J.H.J.P.; Supervision, G.P.G.
DECLARATION OF INTERESTS
G.P.G. has ownership interest (including patents) in and is a consultant/advi-
sory board member for Naveris, Inc., outside the scope of the present study.
J.S.R.-F. reports personal/consultancy fees from VolitionRx, Page.AI, Gold-
man Sachs, Grail, Ventana Medical Systems, Invicro, Roche Diagnostics,
and Genentech, outside the scope of the present study. J.H.J.P. is a consul-
tant for Ideaya Biosciences, Novus Biologicals, and Atropos Therapeutics,
outside the scope of the present study.
Received: May 23, 2019
Revised: October 30, 2019
Accepted: January 3, 2020
Published: February 4, 2020REFERENCES
Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Bian-
kin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al.; Australian
Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC
MMML-Seq Consortium; ICGC PedBrain (2013). Signatures of mutational pro-
cesses in human cancer. Nature 500, 415–421.
Balestrini, A., Nicolas, L., Yang-Lott, K., Guryanova, O.A., Levine, R.L., Bass-
ing, C.H., Chaudhuri, J., and Petrini, J.H. (2016). Defining ATM-independent
functions of the Mre11 complex with a novel mouse model. Mol. Cancer
Res. 14, 185–195.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
HEK293T/17 cells were obtained from American Type Culture Collection (ATCC, CRL-11268) and were cultured according to man-
ufactures’ specifications. LA-7 cells obtained from American Type Culture Collection (ATCC, CRL-2283). LA-7 cells were maintainede3 Cell Reports 30, 1385–1399.e1–e7, February 4, 2020
in DMEM/F12 medium supplemented with 10% fetal bovine serum, 20 mM HEPES, and 10 ug/ml Insulin (‘‘LA-7 medium’’). Prior to
use as feeder cells, LA-7’s were lethally irradiated with 70 Gy ionizing radiation using a Rad Source RS2000 irradiator.
Primary Murine Mammary Epithelial Cells (pMMECs)
pMMECs were derived by harvesting the 4th and 5th mammary glands from 6-12-week-old female transgenic mice with the desired
genotype. Glands were incubated in Liberase digestion medium (EpiCult-B Mouse Medium Kit (Stem Cell Technologies, 285 Units
Collagenase Type 3 (Worthington), 20mM HEPES (GIBCO), 20 ug/mL Liberase Blendzyme 2 (Roche) and shaken (vertically) at 37C
overnight. The resulting digestion was spun down and resuspended in 3 mls trypsin with EDTA and 1000U DNase and incubated at
37C for 5 min. LA-7 medium (DMEM-F12 media, 10% FBS, 20 mM HEPES, 10 mg/mL Insulin, 1X L-glutamine, 1X Penicillin-Strep-
tomycin) was added to neutralize the trypsin. Cells were spun down and resuspended in 10U Dispase (Stem Cell Technologies)
and 1000U DNase I (Worthington Biochemical) and incubated at 37C for 5 min. Cells were washed twice with LA-7 medium and
the resulting cells were resuspended in EpiCult-B Mouse Medium Kit (Stem Cell Technologies) and seeded onto Cultrex 3D-Culture
Matrix (Trevigen) coated 6 well plates. For longer term cell growth experiments, pMMECs were seeded on lethally irradiated LA-7
cells and cultured in LA-7 medium. All cells were cultured to 80% confluence then passaged by trypsinization. Cells were tested
monthly for mycoplasma using PlasmoTest Kit.
Transgenic Mouse Models
Mice used in this study were housed in the Division of Comparative Medicine at the University of North Carolina at Chapel Hill, a
facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
R26LSL-Cas9 (JAX#024857) and R26LSL-MycOE (JAX#020458) transgenic mouse strains were obtained from the Jackson Laboratory.
Rb1fl/fl and Trp53fl/fl mouse strains were generously provided by the Perou laboratory, and originally obtained from the Frederick
National Laboratory for Cancer Research (Strains #01XC1 and #01XC2). A subset of interbred mouse strains used in this study
were analyzed by the Mouse Universal Genotyping Array (MUGA) from Neogen Genomics, and determined to be > 90% FVB with
a minor contribution from C57BL/6J. For mammary tumor induction studies, six to twelve-week-old female R26Cas9/Cas9; Rb1fl/fl;
Trp53fl/fl mice received bilateral intraductal injections, into the fourth mammary gland, containing 5 3 105 transduction units (TU)
of either LentiCRISPR-Cre-V2-sgControl (Cre-sgControl) or LentiCRISPR-Cre-V2-sgControl (Cre-sgMre11) lentivirus. Mouse co-
horts were palpated for the development of mammary tumors twice weekly, and three times weekly after mammary tumors had
formed. Mice were euthanized using humane experimental endpoints in accordance with UNC Institutional Animal Care and Use
Committee (IACUC) guidelines. At necropsy, mammary tumors were harvested and sectioned into four pieces. Two pieces were
immediately flash frozen for RNA and DNA extraction. One piece with any remaining glands (4th and 5th) were fixed in 4% parafor-
maldehyde and processed for paraffin embedding and H&E staining (Histoserv Inc.). One piece was taken for creation of tumor
lines. Briefly, tumor pieces were incubated in digestion medium (DMEM, 10% FBS, 1mg/ml Collagenase Type 3, 1mg/ml Hyaluron-
idase) and shaken (horizontally) at 37C for four hours. The resulting digestion was spun down and resuspended in trypsin with
DNase and incubated at 37C for 5min. LA-7 medium was added to neutralize the trypsin. Cells were spun down and resuspended
in Dispase and deoxyribonuclease and incubated at 37C for 5min. Cells were washed twice with LA-7medium and passed through a
70 mm filter. The resulting cells were resuspended in LA-7 media and seeded into co-culture with irradiated LA-7 feeder cells. The
cells were cultured over 10 passages and analyzed via flow for GFP expression to monitor tumor cell outgrowth. Tumor lines




This plasmid was created by using restriction enzymes (XbaI and BglII) to cut the Cre sequence from the pLV-Cre_LKO1 plasmid
and swapping it for the Cas9 sequence in lentiCRISPR V2 using restriction digest and T4 ligation. In order to get rid of the BsmbI
site within Cre, Gibson cloning was used (HiFi DNA Assembly Master Mix; NEB) to change the sequence of a Valine residue from
GTC to GTA, thus removing the site while preserving the protein sequence. Using the remaining BsmB1 sites, the sequences for
sgControl (53bp1 intron sequence) and sgMre11 were inserted into the sgRNA scaffolding region.
LentiCRISPR-Cre-V2-sgRNA-RNasH1
This plasmid was created via Gibson cloning of the RNaseH1 gene from the pEGFP-RNASEH1 plasmid (Addgene #108699) to
replace the LumiFluor gene in the LentiCRISPR-Cre-V2-sgControl LumiFluor and LentiCRISPR-Cre-V2-sgMre11 LumiFluor
plasmids.
Lentiviral_pRRL-EF1a-NeuT-LumiFluor
This plasmid was created via Gibson cloning of the Lentiviral_pRRL-EF1a-GpNLuc plasmid to insert the NeuT gene (constitutively
active truncation mutant of Neu, the rodent ortholog of Her2) and an autocleavage P2A sequence upstream of the luciferase
gene. NeuT-P2A was synthesized as a gene block (IDT), using pSV2-NeuT (Addgene #10919) as the reference sequence. Because
NeuT is commonly used to recapitulate Her2-initiated tumorigenesis, we refer to this construct as ‘‘Her2’’ in the text and figures of the
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All plasmids created were confirmed by Sanger sequencing (Eton Bioscience Inc.). LentiCRISPR-Cre-V2-sgControl-Lumifluor,
LentiCRISPR-Cre-V2-sgMre11-Lumifluor, LentiCRISPR-Cre-V2-sgControl-RNaseH1, LentiCRISPR-Cre-V2-sgMre11-RNaseH1,
Lentiviral_pRRL-EF1a-GpNLuc, and Lentiviral_pRRL-EF1a-NeuT-LumiFluor will be made available by the Lead Contact.
Topo cloning
pMMECs were infected twice with either Cre-sgControl or Cre-sgMre11. Upon confirmation of at least 80% viral efficiency, Topo
Cloning was performed per manufactures protocol. Sequencing was performed by Eton Biosciences and analysis performed using
Bioedit software.
Immunofluorescence
pMMECs were infected twice with either Cre-sgControl, Cre-sgMre11, GFP, or NeuT virus. Upon confirmation of at least 80% viral
efficiency, cells were seeded onto 3D-matrix coated coverslips, were treated with EdU for 10 min, and subsequently fixed by cold
Methanol:Acetone (1:1) incubation at 20C for 10 mins. Cells then underwent EdU detection using the EdU detection kit (Baseclick)
in accordance with kit instructions. Cells were then blocked in PBS + 5% FBS for 1 hour, followed by incubation in the appropriate
primary antibody for 1 hour (p-gH2AX; 53bp1; p-RPA2; or S9.6), secondary antibody for 30 min, then DAPI for 1 min. Coverslips were
then mounted onto slides with Prolong Gold mounting medium, cured for 2 hours and stored at 4C in the dark until imaging. Cover-
slips were examined on an Olympus BX61 upright wide field microscope. Resulting foci were analyzed using Fiji software (Schindelin
et al., 2012).
Comet assay
pMMECs were infected twice with either Cre-sgControl, Cre-sgMre11, GFP, or NeuT virus and confirmation of at least 80% viral ef-
ficiency was determined by Flow Cytometry (Attune NxT) for GFP expression. The presence of SSBs and DSBs were analyzed via
Alkaline (SSBs/DSBs) and Neutral (DSBs) comet assay using the Trevigen comet assay kit according to manufacturer’s protocol.
Comet images were captured by fluorescence microscopy using Olympus BX61 upright wide field microscope. The tail DNA percent
was quantified using the ImageJ software with OpenComet plug-in (Gyori et al., 2014).
Growth assays
pMMECs were infected twice with either Cre-sgControl or Cre-sgMre11 virus then seeded into 12 well plates at a density of 3 X 104
cells/well onto LA-7 feeder cells. Duplicate samples were harvested every 2-3 days for 15 days. Total cells/well were counted, cells
were fixed in 3% PFA and subjected to flow analysis (Attune NxT) for the presence of GFP. Prior to ATMi growth assays, the dose of
ATMi that resulted in 50% and 100% inhibition of the ATM pathway was determined. Wild-type mouse embryonic fibroblasts (MEFs)
were treated with 0, 1, 3, 5, 7, 10, 15, or 20 uM of the ATM inhibitor Ku55933 for 30min. They were then subjected to 10 Gy, incubated
under normal culture conditions and then cell lysate was collected for western blotting analysis of the phosphorylated form of the
ATM downstream protein, Kap1. For ATMi growth assays pMMECs were treated as above but with the additional presence of either
5 or 10 uM of ATMi.
Viral production and infection
HEK293T/17 cells were transfected, using Polyethylenimine (PEI), with viral packaging plasmids, psPax2 and pMD2.G, and either
LentiCRISPR-Cre-V2-sgControl-Lumifluor, LentiCRISPR-Cre-V2-sgMre11-Lumifluor, Lentiviral_pRRL-EF1a-GpNLuc, or Lentivir-
al_pRRL-EF1a-NeuT-LumiFluor, LentiCRISPR-Cre-V2-sgControl-RNaseH1, or LentiCRISPR-Cre-V2-sgMre11-RNaseH1 plasmids.
Twenty-four hours post transfection, cells were washed and refedwith freshmedium. Viral containingmediawas collected for 3 days.
Collected media was filtered (0.45 um) then spun down for 2 hours at 16C at 21,000 rpm. Virus containing pellet was resuspended in
PBS and incubated at 4C for 24 hours then aliquoted and stored at 80C. For lentiviral infections, cells were transduced with the
appropriate virus combined with 4mg/ml Polybrene overnight. Cells were refed with fresh viral containing medium and incubated
overnight two to three times (2-3 back to back infections). Following the last infections cells were washed three times with PBS
and cultured with MEGM. For testing viral efficacy, a small sample of cells were fixed with 3% Paraformaldehyde (PFA) and were
assessed via flow cytometry (Attune NxT) for the presence of GFP indicating Cas9 expression or were stained with anti-CD2-PE indi-
cating Myc expression.
Chemotherapeutic and inhibitor sensitivity assays
Tumor cells were seeded at a density of 1500 cells per well of a 96 well dish and allowed to attach overnight. After the cells were
attached, various drugs or DMSO control were added to the media to the final concentrations shown in the figures. Each treatment
was done in triplicate. Cells underwent IncuCyte live cell imaging (S‘artorius), scanned every two hours to determine cell confluence
and growth rates over seven days.
Automated analysis of mouse mammary tissues
The process of quantitative image analysis begins with the acquisition of high-resolution digital slides. FFPE sections of mousemam-
mary tissue stained with hematoxylin and eosin were scanned on an Aperio ScanScope XT (Leica Biosystems). Images were thene5 Cell Reports 30, 1385–1399.e1–e7, February 4, 2020
uploaded to eSlide Manager and visualized with ImageScope 12.3 (Leica Biosystems). Separate tissue sections on each image were
annotated by KFS. Mouse mammary glands four and five were differentiated based on the location of the lymph node which sepa-
rates the glands. The annotated images were then imported to Definiens Architect XD 2.7.0 Build 60765 x64 for analysis with Tissue
Studio version 4.4.2. Using the Tissue Studio portal, the annotated images were preselected for region-of-interest (ROI) detection.
The Definiens Composer algorithm was used to segment the tissue into different ROIs: Brown Adipose, Epithelium, RBCs, Stroma,
Glass, and White Adipose. This algorithm was trained on representative regions to classify all the tissue within the ROIs in the final
analysis. The program then calculated the total tissue area and the area percentages for each of the ROIs. In addition, the program
was configured to detect and score nuclei within each of the ROIs, based on a hematoxylin stain threshold and average size set by the
analyst. All nuclei were counted and classified as small (< 20 mm2), medium (20 – 40 mm2), or large (> 40 mm2). These values were used
to calculate a histological score equal to (1 x % nuclei small) + (2 x % nuclei medium) + (3 x % nuclei large). The analysis output
included all quantitative results as well as screen captures of the ROI detection plus overlays and the cellular analysis (nuclei). Slide
scanning and tissue quantification was performed by the Bentley R. Midkiff at the Translational Pathology Lab at UNC.
Human breast cancer tissue microarrays
Tissue microarrays were constructed from 271 patients with non-metastatic TNBC (ER/PR < 1%; HER2 0/1+, or HER2 2+/FISH
not amplified) who underwent surgical resection of their primary tumor at our institution between 2002 and 2007. Exclusion criteria
were < 1 cm primary tumor size, prior breast radiation, inflammatory breast cancer, and neoadjuvant chemotherapy. Immunohisto-
chemistry (IHC) was performed using rabbit polyclonal anti-sera generated against humanMre11 (1:3000) and human Nbs1 (1:3000).
Tumors were classified as low-expressors of the Mre11 complex if < 10% of cancer cells had detectable nuclear protein expression
of Mre11 and/or Nbs1 relative to background staining levels, and determined by two independent reviewers. 254 out of 271 cases
were deemed evaluable. Lack of immunoreactivity was confirmed by repeating the IHC using whole tissue sections in a subset of
Mre11 complex low-expressors.
QUANTIFICATION AND STATISTICAL ANALYSIS
Single cell whole genome sequencing
Mammary epithelial cells for single cell sequencing were derived from littermate WT and Mre11ATLD1/ATLD1 female mice. Lentivirus
expressing EGFP or EGFP+HER2 was added to the cells for 24 hours. Following this infection, the cells were transferred to
10 cm tissue culture dishes containing irradiated LA7 cell feeder layers. The cells were maintained in culture for 2 weeks at which
time they were dissociated into a single cell suspension and sorted for EGFP positive cells into a 96 well plate. These were used
for the whole genome single cell sequencing described below.
Single cell sequencing libraries were prepared using the WGA4 kit (Sigma-Aldrich) as previously described (Garvin et al., 2015;
Martelotto et al., 2017). Half of the individual cell libraries (48/96) were pooled into each of two library pools. Each pool was run
on a single lane for 100-cycle single end sequencing (HiSeq2500, Illumina). The resulting FASTQ files and a bed file defining the
indices for the pool, were used as input into Völur (https://github.com/pkMyt1/Volur). The pipeline trimmed 27 nucleotides from
the end of each read, aligned the reads to the GRCm38 reference with BowTie2 (Langmead and Salzberg, 2012), converted the
SAM files to BAM with SamTools (Li et al., 2009), and output gzipped, demultiplexed BED files suitable for use with Ginkgo (Garvin
et al., 2015). Ginkgo was run using a variable 25 Kb segment size, 76 base pair bowtie simulated reads, and global (sample with
lowest LOD) segmentation. All other parameters were left as the default. Once Ginkgo completed the segment copy data file was
downloaded. This file wasmodified by removing the chromosome-Y elements, masking alignment errors by setting the copy number
in those regions to 2, and normalizing any cell called triploid to diploid. Chromosome Y was removed because these were female
mice. These mice are not the same genetic background as the GRCm38 reference. This resulted in regions of copy gain or loss com-
mon to all samples.
Quantification and statistical analysis
Sincewe did not provide a known diploid sample for Ginkgo to use as a reference, any cell that was scored as being triploid byGinkgo
was adjusted by subtracting 1 from the copy value of each segment. Segments observed in the Mre11 ATLD1 cells that were likely
mapping errors because of the mouse strain used were masked by setting those regions to a copy number of 2 creating a no triploid,
Mre11ATLD1masked segment copy bed file. Ginkgo defines the copy number based on howmany reads mapped to each predefined
segment. The mapped reads for this determination may cross the segment boundaries. Because of this the copy number transition
cannot be assigned to the segment boundaries. To account for this uncertainty, we use a breakpoint for our analysis. We define a
breakpoint region as the start coordinate of the preceding segment through the stop coordinate of the segment containing the
copy number change. Using the masked segment copy file, the number and location of each breakpoint was derived for each
cell type. The unique breakpoints were then intersected with bed files of interest using BedTools (Quinlan and Hall, 2010) via the Py-
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Statistical significance of breakpoint region intersects
The determination that an observed set of breakpoint regions is enriched for overlap with annotated genome regions (e.g., genes,
obtained from http://www.Ensembl.org//useast.ensembl.org/?redirectsrc=//www.ensembl.org%2F) was based on generation of
an empirical null distribution dataset by randomly shuffling the genomic locations of the individual breakpoint regions for each cell
and then determining the frequency of intersects with the genome feature of interest. This process was repeated 10,000 times for
each intersect set. The observed frequency of intersection value was considered significantly different than the randomly shuffled
dataset if it was < 5% or > 95% of this empirical null distribution. Specific association with a target set was defined as being those
target sets that were not enriched for the control cells but were enriched for the oncogene expressing or Mre11ATLD1 cells.
Tumor whole genome sequencing
Whole genome sequencing services were provided by Novogene. Reads were trimmed using SeqPurge (Sturm et al., 2016), aligned
to the mm10 mouse reference using bwa-mem (Li, 2013) and subsequently realigned with ABRA2 (Mose et al., 2019). The resultant
BAM files were sorted and duplicate marked using biobambam2 (Tischler and Leonard, 2014). Small variants were called using
Strelka2, Mutect2 and Cadabra (Cibulskis et al., 2013; Kim et al., 2018; Mose et al., 2019). Mutect2 calls were filtered using the
GATK’s best practices whereas the Strelka2 and Cadabra default filters were applied. Quality thresholds were used to filter calls
using values of QSS_NT > = 70 and QSI_NT > = 40 for Strelka2, SNV TLOD > = 9 and Indel TLOD > = 10 for Mutect2, and
QUAL > = 15 for Cadabra. Variants were additionally filtered using a panel of normals constructed using the Mutect2-GATK best
practices. Structural variants were called usingManta (Chen et al., 2016) and copy number variants were called with CNVKit (Talevich
et al., 2016). Mutation signature analysis was performed using deconstructSigs (Rosenthal et al., 2016). Circos plots were created
with Circa (http://omgenomics.com/circa).
Statistical Analyses
Two-tailed statistical tests for experimental data were conducted using Graphpad Prism version 8. The specific test used in each
analysis is indicated in the corresponding figure legend.
DATA AND CODE AVAILABILITY
The custom algorithms developed for this study are available at https://github.com/pkMyt1/Volur. Whole genome sequencing reads
for murine breast cancers with matched normal liver have been uploaded to NCBI Sequence Read Archive (SRA) with accession
number PRJNA595908. Single cell whole genome sequencing BAM files and copy number segment files have not been uploaded
to SRA due to data format incompatibility, and can be requested from the Lead Contact.e7 Cell Reports 30, 1385–1399.e1–e7, February 4, 2020
